Higher Colonic Tissue Drug Concentrations of Subcutaneous Compared to Intravenous Administration of Infliximab Therapy in Patients With Inflammatory Bowel Disease

Inflammatory Bowel Disease

Higher body mass index is associated with lower drug concentrations in patients with inflammatory bowel disease treated with ustekinumab but not vedolizumab

Inflamm Bowel Dis

Lee J, Porth R, Saraga A, Gade A, Deyhim T, Soliman M, Moini SH, Zullow S, Rabinowitz L, Grossberg L, Cheifetz AS, Papamichael K

doi: 10.1093/ibd/izag139

Inflammatory Bowel Disease

Persistence and safety of subcutaneous infliximab up to 1 year after switching from intravenous infliximab in pediatric inflammatory bowel disease: a multicenter real-world cohort study

Inflamm Bowel Dis

Boute EH, Gianolio L, Mahmmod S, Pochesci S, Armstrong K, Henderson P, Wilson DC, de Ridder L, Russell RK, Escher JC

doi: 10.1093/ibd/izaf335

Inflammatory Bowel Disease

Primary infliximab failure in pediatric colonic inflammatory bowel disease: Development of a proteomics predictive model using a prospective Canadian cohort

Inflamm Bowel Dis

Ricciuto A, Turinsky AL, Griffiths AM, Mack DR, Wine E, Benchimol EI, El-Matary W, Huynh HQ, Carman N, deBruyn JC, Otley AR, Church PC, Jacobson K, Low S, Broer E, Lawrence S, Sherlock M, Deslandres C, Walters TD

doi: 10.1093/ibd/izaf329

Inflammatory Bowel Disease

Comparative analysis of inflammatory bowel disease patient and service reported quality of care using 2019 and 2023 UK benchmarking data from more than 26,000 adult patient respondents and 154 IBD services

J Crohns Colitis

Hawthorne AB, Christiansen P, Arnott I, Cummings F, Dobson L, Kent A, Limdi JK, Mulligan RJ, Parkes GC, Rees F, Selinger CP, Turner J, Woo N, Younge L, Contributors to the IBD UK Task & Finish group, IBD Service Survey Collaborators, Lamb CA

doi: 10.1093/ecco-jcc/jjag005

COMMENTED

Inflammatory Bowel DiseaseFurther Publications

A Prospective Interventional Study to Evaluate the Effect of Hypoxia on Healthy Volunteers and Patients With Inflammatory Bowel Disease: The Altitude Inflammatory Bowel Disease Study

★ 3 Recommended and commented by Prof. Dr Stephan Vavricka, Faculty Member

Am J Gastroenterol

Vavricka SR, Zeitz J, Madanchi M, Ruiz PA, Biedermann L, Morsy Y, Yilmaz B, Scharl M, Scharl S, Gassmann M, Lutz TA, Kunz A, Bron D, Misselwitz B, MacPherson AJ, Rogler G, Greuter T

doi: 10.14309/ajg.0000000000003888

Inflammatory Bowel Disease

Clinical Response for 12 Months or More to the First Advanced Therapy is Associated with a Significant Decrease in the Long-Term Risk of Hospitalization: A Nation-Wide Analysis of Patients From the UK Inflammatory Bowel Disease (IBD) BioResource

Inflamm Bowel Dis

Yan K, Vuyyuru SK, Taylor A, Figueredo G, Raine T, Sanon M, Naessens D, Munje C, Moran GW

doi: 10.1093/ibd/izaf276

Inflammatory Bowel Disease

Inflammatory Bowel Disease therapies and Demyelinating Diseases: A Practical Guide to Therapeutic Benefit and Risk

J Crohns Colitis

Honap S, Debouverie M, Filippi M, Selchen D, Jairath V, Danese S, Peyrin-Biroulet L

doi: 10.1093/ecco-jcc/jjaf215

Inflammatory Bowel Disease

Comparative Risk of Serious Infections Associated With Treatment of Inflammatory Bowel Disease

Inflamm Bowel Dis

Khan N, Sundararajan R, Patel D, Patel M, Bahirwani J, Mahmud N

doi: 10.1093/ibd/izaf218

Inflammatory Bowel Disease

Comprehensive proteomic profile in newly diagnosed patients with inflammatory bowel disease: identification of potential biomarkers

J Crohns Colitis

Baldán-Martín M, Iloro I, Azkargorta M, Soleto I, Orejudo M, Ramirez C, Mercado J, Suárez-Trujillo F, Sánchez-Sánchez C, Garre A, Riestra S, Rivero M, Gutiérrez A, Rodríguez-Lago I, Fernández-Salazar L, Ceballos D, Benítez JM, Aguas M, Bastón-Rey I, Bermejo F, Casanova MJ, Lorente-Poyatos RH, Ber Y, Ginard D, Esteve M, De Francisco R, García MJ, Francés R, Cabriada JL, Soto P, Nos P, Acosta MB, Guerra I, Cruz DH, Domínguez Cajal M, Royo V, Aceituno M, Martín-Cófreces NB, Elortza F, Gisbert JP, Chaparro M

doi: 10.1093/ecco-jcc/jjaf177

Related content

Higher body mass index is associated with lower drug concentrations in patients with inflammatory bowel disease treated with ustekinumab but not vedolizumab

Persistence and safety of subcutaneous infliximab up to 1 year after switching from intravenous infliximab in pediatric inflammatory bowel disease: a multicenter real-world cohort study

Primary infliximab failure in pediatric colonic inflammatory bowel disease: Development of a proteomics predictive model using a prospective Canadian cohort

Comparative analysis of inflammatory bowel disease patient and service reported quality of care using 2019 and 2023 UK benchmarking data from more than 26,000 adult patient respondents and 154 IBD services

A Prospective Interventional Study to Evaluate the Effect of Hypoxia on Healthy Volunteers and Patients With Inflammatory Bowel Disease: The Altitude Inflammatory Bowel Disease Study

Clinical Response for 12 Months or More to the First Advanced Therapy is Associated with a Significant Decrease in the Long-Term Risk of Hospitalization: A Nation-Wide Analysis of Patients From the UK Inflammatory Bowel Disease (IBD) BioResource

Inflammatory Bowel Disease therapies and Demyelinating Diseases: A Practical Guide to Therapeutic Benefit and Risk

Comparative Risk of Serious Infections Associated With Treatment of Inflammatory Bowel Disease

Comprehensive proteomic profile in newly diagnosed patients with inflammatory bowel disease: identification of potential biomarkers